Clinical trial · Interventional
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
A Pan-Cancer Basket, Real World, Open-label, Multicenter Study on Molecular Matching Therapy Guided by Molecular Tumor Boards (MTB) for Pan Solid Tumor Patients With Standard Treatment Exhaustion
NCT06739395CI-TRIAL-00083875recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Precision Medicine | — | UNRESOLVED | — |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (14)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alpelisib Pill | Drug | — | UNRESOLVED |
| Anlotinib | Drug | — | UNRESOLVED |
| Chidamide | Drug | — | UNRESOLVED |
| Dabrafenib | Drug | Dabrafenib | ALIAS |
| Lenvatinib Capsules | Drug | Lenvatinib | ALIAS |
| Olaparib tablet | Drug | Olaparib | ALIAS |
| Palbociclib Pill | Drug | — | UNRESOLVED |
| Pazopanib Pill | Drug | — | UNRESOLVED |
| PD-1/PD-L1/PD-1&CTLA4 inhibitor | Drug |
Design
Arms and outcomes
Arms (9)
- type
- OTHER
- label
- Monotherapy
- description
- In the OncoKB(Precision Oncology Knowledge Base) database, the gene alteration has a variant of clinical evidence in this tumor or other tumor types and is considered to be an interventional variant. Cohort-1may include different observation subgroups（dMMR/MSI-H,TMB-H,NTRK fusion,RET-fusion,BRAF(p.V600E),KRAS(p.G12C),HER2(IHC,3+)）. For example, substudy-1: monotherapy/combination therapy for patients with A1-relative. Substudy-x: monotherapy/combination therapy for patients with Ax-relative.
- interventionNames
- Drug: Target Gene
- type
- EXPERIMENTAL
- label
- Combination therapy-cohort1
- description
- The characteristics of enrolled patients are the presence of two or more interventional or potential actionable targets(only TP53 alteration,MAP2K1 alteration,PMA pathway alteration,11q13 amplification,MET alteration).
- interventionNames
- Drug: Olaparib tablet
- Drug: Temozolomide capsule
- Drug: Anlotinib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology; 2. ECOG score 0-4 (3-4 points only for patients with tumor burden); 3. Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment; 4. At least one measurable lesion that meets the RECIST 1.1 standard; 5. Expected survival period ≥ 3 months; 6. Age ≥ 18 years old; 7. Tumor tissue blocks with sufficient formalin fixed paraffin embedding (FFPE), or chest or ascites with cancer cells detected during treatment (not less than 200ml), or excised metastatic lymph nodes, or peripheral blood (approximately 5m1) can be used for genetic testing; 8. Understand and voluntarily participate in this study, and sign the informed consent form. Exclusion Criteria: 1. Patients who have actively undergone or are currently participating in clinical trials for treatment; 2. Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection, mental diseases/social conditions that limit the compliance with the research requirements) that the researchers think will confuse the research treatment response analysis; 3. Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.
References
Publications (0)
Data not yet available
No reference posted for this study.